1 / 39

(1)

ICMJE Disclosure Form (Feb2021): http://icmje.org Ugeskrift for Læger / Danish Medical Journal Page 1 of 2

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 25. marts 2021

Your name: Trine Alma Knudsen

Manuscript title:Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier som…

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed)

Specifications/Comments

(e.g., if payments were made to you or to your institution)

Time frame: Since the initial planning of the work 1 All support for the present

manuscript (e.g., funding, provision of study

materials, medical writing, article processing charges, etc.)

No time limit for this item.

܈

܈ None

Click TAB in last row to add extra rows Time frame: past 36 months

2 Grants or contracts from any entity(if not indicated in item #1 above).

܈ None

3 Royalties or licenses ܈܈ None

(2)

4 Consulting fees ܈܈ None

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events

܈

܈ None

6 Payment for expert

testimony ܈܈ None

7 Support for attending

meetings and/or travel ܈܈ None

8 Patents planned, issued or

pending ܈܈ None

9 Participation on a Data Safety Monitoring Board or Advisory Board

܈

܈ None

10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid

܈

܈ None

11 Stock or stock options ܈܈ None

12 Receipt of equipment, materials, drugs, medical writing, gifts or other services

܈

܈ None

13 Other financial or non- financial interests

܈

܈ None

Please place an “X” next to the following statement to indicate your agreement:

܈

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(3)

&"&(%"% 5<:<;6.''#.33 /"% &%'"%%3!&"(%! ;"<

&&)3+#"%''!"% &"%&( ''!''"&%'"%%"%!&"(%!/

'. 26. marts 2021

"(%! . Anders Lindholm Sørensen

!(&%#'''. Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier som Modelsygdomme

D M l lif i N l i M d l d

!(&%#'!( %5!"*!6.

!'!'%&'"'%!&#%!,-*&,"('"&"&%'"!&#&3')'&3!'%&'&&'"*''

%%''"'"!'!'","(% !(&%#'/1'2 !&!,%'"!*'"%4#%"'"%!"'4"%4#%"' '%#%'&*"&!'%&'& ,','"!'!'"' !(&%#'/&"&(%%#%&!'&

" ' !''"'%!&#%!,!"&!"'!&&%,!'&/ ,"(%!"('"('*'%'"

&'%'"!&#3')',3!'%&'-'&#%%'',"("&"/

""*!$(&'"!&##,'"'('"%0&%'"!&#&3')'&3!'%&'&&',%''"'(%%!' !(&%#'"!,/

('"%0&%'"!&#&3')'&3!'%&'&&"(!%",/"%+ #-,"(% !(&%#'

#%'!&'"'# "",",#%'!&"!-,"(&"(%%'"!&#&*' !('(%%&"

!',#%'!&) '"!-)!'' '"!&!"' !'"!!' !(&%#'/

!' 7;"*-%#"%'&(##"%'"%'*"%%#"%'!'& !(&%#'*'"('' '/"%

"'%' &-'' % "%&"&(%&'#&'=@ "!'&/

!''&*'

*" ,"()'&

%'"!&#"%!'

!"!3%"*&&

!4

#'"!&2" !'&

3//-#, !'&*% '","("%'","(%

!&''('"!4

% .!'!'#!!!"'*"%

; &(##"%'"%'#%&!' !(&%#'5//-(!!-

#%")&"!"&'(,

'%&- *%'!-

%'#%"&&!%&- '/6

"' '"%'&

' /

"!

!&'%"*'"+'%%"*&

% .#&'78 "!'&

< %!'&"%"!'%'&%"

!,!'',5!"'!'

!' 7;")6/

"!

= ",'&"%!&&

"!

(4)

&"&(%"% 5<:<;6.''#.33 /"% &%'"%%3!&"(%! <"<

> "!&('!&

"!

? , !'"%"!"%%"%

'(%&-#%&!''"!&-

&#%&(%(&- !(&%#'*%'!"%

('"!)!'&

"!

@ , !'"%+#%' '&' "!,

"!

A (##"%'"%''!!

'!&!3"%'%) "!

B '!'&#!!-&&("%

#!! "!

C %'#'"!"!' ',"!'"%!"%

"%)&"%,"%

"!

;: %&#"%(%,

%"!"'%"%-

&"',-" ''"%

)",%"(#-#"%

(!#

"!

;; '""%&'""#'"!&

"!

;< #'"$(# !'- '%&-%(&-

*%'!-'&"%"'%

&%)&

"!

;= '%!!"%!"!4

!!!'%&'& "!

&#!01!+''"'""*!&'' !''"!',"(%% !'.

%','')!&*%)%,$(&'"!!)!"''%'*"%!"!,"'

$(&'"!&"!'&"% /

"%&%'"% %5!&"(%!

&&)3+#"%''!"% &"%&( ''!''"&%'"%%"%!&

"(%!/

(5)

ICMJE DISCLOSURE FORM

Date:^24.^februar²⁰²¹

Your name:^Morten^Kranker^Larsen

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier som Modelsygdom

܈

܈ None

܈ None

(6)

܈

܈ None

6 Payment for expert testimony

܈

܈ None

7 Support for attending meetings and/or travel

܈

܈ None

8 Patents planned, issued or pending

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

13 Other financial or non-

financial interests ܈܈ None

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(7)

(8)

(9)

(10)

(11)

ICMJE DISCLOSURE FORM

Date: 27. marts 2021

Your name:^Gitte^Thomsen

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom. De MyeloproliferativeNeoplasier som modelsygdomme

܈

܈ None

܈ None

(12)

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(13)

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 25. marts 2021

Your name: Christina Ellervik

Manuscript title: Forhøjede blodcelletal…….

Manuscript number (if known):

Name all entities with whom you have this relationship or indicate none (add rows as needed)

Specifications/Comments

(e.g., if payments were made to you or to your institution)

Time frame: Since the initial planning of the work 1 All support for the present

No time limit for this item.

܈

܈ None

Click TAB in last row to add extra rows Time frame: past 36 months

܈ None

3 Royalties or licenses ܈ None

(14)

܈ None

testimony ܈ None

meetings and/or travel ܈ None

pending ܈ None

܈ None

11 Stock or stock options ܈ None

܈ None

Please place an “X” next to the following statement to indicate your agreement:

܈

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

(15)

ICMJE DISCLOSURE FORM

Your name: Troels Wienecke

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier Manuscript number (if known): ǦͲ͵ǦʹͳǦͲʹͺʹ

܈

܈ None

(16)

܈ None

testimony ܈ None

pending ܈ None

܈ None

܈

(17)

ICMJE DISCLOSURE FORM

Date: 25. marts 2021

Your name: Niels Eske Bruun

Manuscript title:

܈

܈ None

܆ None I have received a Clinical Trial grant from the Novo Nordisk Foundation, not related to the present work

(18)

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

11 Stock or stock options ܈܈ None Related to the present work

܈

܈ None

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(19)

(20)

ICMJE DISCLOSURE FORM

Your name: Vibe Skov

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom.

܈

܈ None

(21)

܈ None

testimony ܈ None

pending ܈ None

܈ None

܈

(22)

ICMJE DISCLOSURE FORM

Date: 29. marts 2021

Your name:^Marie^Bak

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier som Modelsygdomme.

܈

܈ None

܈ None

(23)

܈

܈ None

testimony ܈܈ None

meetings and/or travel ܈܈ None

pending ܈܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(24)

(25)

ICMJE DISCLOSURE FORM

Date: 25. marts 2021

Your name: Sarah Friis Christensen

Manuscript title:Forhøjede Blodcelletal og Vaskulær Sygdom. De Myeloproliferative Neoplasier som Modelsygdomme

Manuscript number (if known):UFL-03-21-0282

܈

܈ None

Click TAB in last row to add extra rows

(26)

ICMJE Disclosure Form (Feb2021): http://icmje.org Ugeskrift for Læger / Danish Medical Journal Page 2 of 3 Time frame: past 36 months

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

financial interests ܆܆ None

Novartis Collaboration on MPN research project without relation to this article.

(27)

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(28)

(29)

(30)

ICMJE DISCLOSURE FORM

Date: 8. april 2021

Your name: Hans Hasselbalch

Manuscript title: Forhøjede Blodcelletal og Vaskulær Sygdom.

܈

܈ None

܆ None Novartis Grant AOP Orphan Advisory Board

(31)

܆ None AOP Orphan

܈ None

܆ None AOP Orphan

܈ None

܈

(32)

(33)

(34)

ICMJE DISCLOSURE FORM

Date: 26. marts 2021

Your name: Christina Schjellerup Eickhardt-Dalbøge

Manuscript title: Forhøjede blodcelletal og Vaskulær sygdom. De myeloproliferative sygdomme som

܈

܈ None

܈ None

(35)

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

܈ None

܈

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish

Medical Journal.

(36)

(37)

(38)

/D:ŝƐĐůŽƐƵƌĞ&Žƌŵ;&ĞďϮϬϮϭͿ͗ŚƚƚƉ͗ͬͬŝĐŵũĞ͘ŽƌŐ hŐĞƐŬƌŝĨƚĨŽƌ>čŐĞƌͬĂŶŝƐŚDĞĚŝĐĂů:ŽƵƌŶĂů WĂŐĞϭŽĨϮ

/D:/^>K^hZ&KZD

WůĞĂƐĞƐĂǀĞͬĞǆƉŽƌƚƚŚĞĨŝůůĞĚŝŶĨŽƌŵĂƐW&ďĞĨŽƌĞƐƵďŵŝƚƚŝŶŐŝƚƚŽhŐĞƐŬƌŝĨƚĨŽƌ>čŐĞƌŽƌĂŶŝƐŚDĞĚŝĐĂů:ŽƵƌŶĂů͘

ĂƚĞ͗^PDUWV

zŽƵƌŶĂŵĞ͗ /DVVH.M U

DĂŶƵƐĐƌŝƉƚƚŝƚůĞ͗ 0DWHPDWLVNV\JGRPVPRGHOOHULQJELRPHGLFLQHRJV\JGRPVIRUVWnHOVH DĂŶƵƐĐƌŝƉƚŶƵŵďĞƌ;ŝĨŬŶŽǁŶͿ͗

/ŶƚŚĞŝŶƚĞƌĞƐƚŽĨƚƌĂŶƐƉĂƌĞŶĐǇ͕ǁĞĂƐŬǇŽƵƚŽĚŝƐĐůŽƐĞĂůůƌĞůĂƚŝŽŶƐŚŝƉƐͬĂĐƚŝǀŝƚŝĞƐͬŝŶƚĞƌĞƐƚƐůŝƐƚĞĚďĞůŽǁƚŚĂƚ ĂƌĞƌĞůĂƚĞĚƚŽƚŚĞĐŽŶƚĞŶƚŽĨǇŽƵƌŵĂŶƵƐĐƌŝƉƚ͘͞ZĞůĂƚĞĚ͟ŵĞĂŶƐĂŶǇƌĞůĂƚŝŽŶǁŝƚŚĨŽƌͲƉƌŽĨŝƚŽƌŶŽƚͲĨŽƌͲƉƌŽĨŝƚ ƚŚŝƌĚƉĂƌƚŝĞƐǁŚŽƐĞŝŶƚĞƌĞƐƚƐŵĂǇďĞĂĨĨĞĐƚĞĚďǇƚŚĞĐŽŶƚĞŶƚŽĨƚŚĞŵĂŶƵƐĐƌŝƉƚ͘ŝƐĐůŽƐƵƌĞƌĞƉƌĞƐĞŶƚƐĂ ĐŽŵŵŝƚŵĞŶƚƚŽƚƌĂŶƐƉĂƌĞŶĐǇĂŶĚĚŽĞƐŶŽƚŶĞĐĞƐƐĂƌŝůǇŝŶĚŝĐĂƚĞĂďŝĂƐ͘/ĨǇŽƵĂƌĞŝŶĚŽƵďƚĂďŽƵƚǁŚĞƚŚĞƌƚŽ ůŝƐƚĂƌĞůĂƚŝŽŶƐŚŝƉͬĂĐƚŝǀŝƚǇͬŝŶƚĞƌĞƐƚ͕ŝƚŝƐƉƌĞĨĞƌĂďůĞƚŚĂƚǇŽƵĚŽƐŽ͘

dŚĞĨŽůůŽǁŝŶŐƋƵĞƐƚŝŽŶƐĂƉƉůǇƚŽƚŚĞĂƵƚŚŽƌ͛ƐƌĞůĂƚŝŽŶƐŚŝƉƐͬĂĐƚŝǀŝƚŝĞƐͬŝŶƚĞƌĞƐƚƐĂƐƚŚĞǇƌĞůĂƚĞƚŽƚŚĞĐƵƌƌĞŶƚ ŵĂŶƵƐĐƌŝƉƚŽŶůǇ͘

dŚĞĂƵƚŚŽƌ͛ƐƌĞůĂƚŝŽŶƐŚŝƉƐͬĂĐƚŝǀŝƚŝĞƐͬŝŶƚĞƌĞƐƚƐƐŚŽƵůĚďĞĚĞĨŝŶĞĚďƌŽĂĚůǇ͘&ŽƌĞǆĂŵƉůĞ͕ŝĨǇŽƵƌŵĂŶƵƐĐƌŝƉƚ ƉĞƌƚĂŝŶƐƚŽƚŚĞĞƉŝĚĞŵŝŽůŽŐǇŽĨŚǇƉĞƌƚĞŶƐŝŽŶ͕ǇŽƵƐŚŽƵůĚĚĞĐůĂƌĞĂůůƌĞůĂƚŝŽŶƐŚŝƉƐǁŝƚŚŵĂŶƵĨĂĐƚƵƌĞƌƐŽĨ ĂŶƚŝŚǇƉĞƌƚĞŶƐŝǀĞŵĞĚŝĐĂƚŝŽŶ͕ĞǀĞŶŝĨƚŚĂƚŵĞĚŝĐĂƚŝŽŶŝƐŶŽƚŵĞŶƚŝŽŶĞĚŝŶƚŚĞŵĂŶƵƐĐƌŝƉƚ͘

/ŶŝƚĞŵηϭďĞůŽǁ͕ƌĞƉŽƌƚĂůůƐƵƉƉŽƌƚĨŽƌƚŚĞǁŽƌŬƌĞƉŽƌƚĞĚŝŶƚŚŝƐŵĂŶƵƐĐƌŝƉƚǁŝƚŚŽƵƚƚŝŵĞůŝŵŝƚ͘&ŽƌĂůů ŽƚŚĞƌŝƚĞŵƐ͕ƚŚĞƚŝŵĞĨƌĂŵĞĨŽƌĚŝƐĐůŽƐƵƌĞŝƐƚŚĞƉĂƐƚϯϲŵŽŶƚŚƐ͘

EĂŵĞĂůůĞŶƚŝƚŝĞƐǁŝƚŚ

ǁŚŽŵǇŽƵŚĂǀĞƚŚŝƐ ƌĞůĂƚŝŽŶƐŚŝƉŽƌŝŶĚŝĐĂƚĞ ŶŽŶĞ;ĂĚĚƌŽǁƐĂƐ ŶĞĞĚĞĚͿ

^ƉĞĐŝĨŝĐĂƚŝŽŶƐͬŽŵŵĞŶƚƐ

;Ğ͘Ő͕͘ŝĨƉĂǇŵĞŶƚƐǁĞƌĞŵĂĚĞƚŽǇŽƵŽƌƚŽǇŽƵƌ ŝŶƐƚŝƚƵƚŝŽŶͿ

dŝŵĞĨƌĂŵĞ͗^ŝŶĐĞƚŚĞŝŶŝƚŝĂůƉůĂŶŶŝŶŐŽĨƚŚĞǁŽƌŬ ϭ ůůƐƵƉƉŽƌƚĨŽƌƚŚĞƉƌĞƐĞŶƚ

ŵĂŶƵƐĐƌŝƉƚ;Ğ͘Ő͕͘ĨƵŶĚŝŶŐ͕

ƉƌŽǀŝƐŝŽŶŽĨƐƚƵĚǇ

ŵĂƚĞƌŝĂůƐ͕ŵĞĚŝĐĂůǁƌŝƚŝŶŐ͕

ĂƌƚŝĐůĞƉƌŽĐĞƐƐŝŶŐĐŚĂƌŐĞƐ͕

ĞƚĐ͘Ϳ

EŽƚŝŵĞůŝŵŝƚĨŽƌƚŚŝƐ ŝƚĞŵ͘

܈EŽŶĞ

ůŝĐŬdŝŶůĂƐƚƌŽǁƚŽĂĚĚĞǆƚƌĂƌŽǁƐ dŝŵĞĨƌĂŵĞ͗ƉĂƐƚϯϲŵŽŶƚŚƐ

Ϯ 'ƌĂŶƚƐŽƌĐŽŶƚƌĂĐƚƐĨƌŽŵ ĂŶǇĞŶƚŝƚǇ;ŝĨŶŽƚŝŶĚŝĐĂƚĞĚ ŝŶŝƚĞŵηϭĂďŽǀĞͿ͘

܈EŽŶĞ

ϯ ZŽǇĂůƚŝĞƐŽƌůŝĐĞŶƐĞƐ

܈EŽŶĞ

(39)

/D:ŝƐĐůŽƐƵƌĞ&Žƌŵ;&ĞďϮϬϮϭͿ͗ŚƚƚƉ͗ͬͬŝĐŵũĞ͘ŽƌŐ hŐĞƐŬƌŝĨƚĨŽƌ>čŐĞƌͬĂŶŝƐŚDĞĚŝĐĂů:ŽƵƌŶĂů WĂŐĞϮŽĨϮ

ϰ ŽŶƐƵůƚŝŶŐĨĞĞƐ

܈EŽŶĞ

ϱ WĂǇŵĞŶƚŽƌŚŽŶŽƌĂƌŝĂĨŽƌ ůĞĐƚƵƌĞƐ͕ƉƌĞƐĞŶƚĂƚŝŽŶƐ͕

ƐƉĞĂŬĞƌƐďƵƌĞĂƵƐ͕

ŵĂŶƵƐĐƌŝƉƚǁƌŝƚŝŶŐŽƌ ĞĚƵĐĂƚŝŽŶĂůĞǀĞŶƚƐ

܈EŽŶĞ

ϲ WĂǇŵĞŶƚĨŽƌĞǆƉĞƌƚ ƚĞƐƚŝŵŽŶǇ

܈EŽŶĞ

ϳ ^ƵƉƉŽƌƚĨŽƌĂƚƚĞŶĚŝŶŐ

ŵĞĞƚŝŶŐƐĂŶĚͬŽƌƚƌĂǀĞů ܈EŽŶĞ

ϴ WĂƚĞŶƚƐƉůĂŶŶĞĚ͕ŝƐƐƵĞĚŽƌ

ƉĞŶĚŝŶŐ ܈EŽŶĞ

ϵ WĂƌƚŝĐŝƉĂƚŝŽŶŽŶĂĂƚĂ

^ĂĨĞƚǇDŽŶŝƚŽƌŝŶŐŽĂƌĚ ŽƌĚǀŝƐŽƌǇŽĂƌĚ

܈EŽŶĞ

ϭϬ >ĞĂĚĞƌƐŚŝƉŽƌĨŝĚƵĐŝĂƌǇ ƌŽůĞŝŶŽƚŚĞƌďŽĂƌĚ͕

ƐŽĐŝĞƚǇ͕ĐŽŵŵŝƚƚĞĞŽƌ ĂĚǀŽĐĂĐǇŐƌŽƵƉ͕ƉĂŝĚŽƌ ƵŶƉĂŝĚ

܈EŽŶĞ

ϭϭ ^ƚŽĐŬŽƌƐƚŽĐŬŽƉƚŝŽŶƐ

܈EŽŶĞ

ϭϮ ZĞĐĞŝƉƚŽĨĞƋƵŝƉŵĞŶƚ͕

ŵĂƚĞƌŝĂůƐ͕ĚƌƵŐƐ͕ŵĞĚŝĐĂů ǁƌŝƚŝŶŐ͕ŐŝĨƚƐŽƌŽƚŚĞƌ ƐĞƌǀŝĐĞƐ

܈EŽŶĞ

ϭϯ KƚŚĞƌĨŝŶĂŶĐŝĂůŽƌŶŽŶͲ

ĨŝŶĂŶĐŝĂůŝŶƚĞƌĞƐƚƐ ܈EŽŶĞ

WůĞĂƐĞƉůĂĐĞĂŶ͞y͟ŶĞǆƚƚŽƚŚĞĨŽůůŽǁŝŶŐƐƚĂƚĞŵĞŶƚƚŽŝŶĚŝĐĂƚĞǇŽƵƌĂŐƌĞĞŵĞŶƚ͗

܈

/ĐĞƌƚŝĨǇƚŚĂƚ/ŚĂǀĞĂŶƐǁĞƌĞĚĞǀĞƌǇƋƵĞƐƚŝŽŶĂŶĚŚĂǀĞŶŽƚĂůƚĞƌĞĚƚŚĞǁŽƌĚŝŶŐŽĨĂŶǇŽĨƚŚĞ ƋƵĞƐƚŝŽŶƐŽŶƚŚŝƐĨŽƌŵ͘

/DWKZdEdĨŽƌhŐĞƐŬƌŝĨƚĨŽƌ>čŐĞƌΘĂŶŝƐŚDĞĚŝĐĂů:ŽƵƌŶĂů

WůĞĂƐĞƐĂǀĞͬĞǆƉŽƌƚƚŚĞĨŝůůĞĚŝŶĨŽƌŵĂƐW&ďĞĨŽƌĞƐƵďŵŝƚƚŝŶŐŝƚƚŽhŐĞƐŬƌŝĨƚĨŽƌ>čŐĞƌŽƌĂŶŝƐŚ DĞĚŝĐĂů:ŽƵƌŶĂů͘